Frequency Associated Suppression of Tremor in Parkinson’s Disease and Essential Tremor
- Conditions
- Parkinson's Disease, Essential Tremor
- Registration Number
- DRKS00032470
- Lead Sponsor
- niversität zu Köln, Zentrum für Klinische Studien Köln
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Uni- or bilateral implantation of DBS leads in the subthalamic nucleus (PD) or the ventral intermedius nucleus of the thalamus and the posterior subthalamic area (ET) at least 3 months prior to study inclusion and confirmed diagnosis of Parkinson's Disease or Essential Tremor.
Patients with Parkinson’s Disease must have a relevant tremor burden defined as = 2 of 4 points of the MDS-UPDRS item 3.17 (rest tremor) without medication, patients with Essential Tremor =2 of 4 points of item 5/6 of the Fahn Tolosa Marin Tremor Rating Scale (postural or intention tremor).
Patients must be able to consent to participate at the study and to give written informed consent prior to study inclusion.
Non-fulfillment of all inclusion criteria
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in tremor suppression, assessed by accelerometry, with energy-equivalent stimulation using two different stimulation frequencies (130 Hz vs 185 Hz)
- Secondary Outcome Measures
Name Time Method -Amplitude-equivalent effects of the different frequencies on tremor<br>- effects on therapeutic window<br>- for PD, effects on rigidity and bradykinesia